1511 related articles for article (PubMed ID: 27095655)
1. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).
Banales JM; Cardinale V; Carpino G; Marzioni M; Andersen JB; Invernizzi P; Lind GE; Folseraas T; Forbes SJ; Fouassier L; Geier A; Calvisi DF; Mertens JC; Trauner M; Benedetti A; Maroni L; Vaquero J; Macias RI; Raggi C; Perugorria MJ; Gaudio E; Boberg KM; Marin JJ; Alvaro D
Nat Rev Gastroenterol Hepatol; 2016 May; 13(5):261-80. PubMed ID: 27095655
[TBL] [Abstract][Full Text] [Related]
2. Targeting cholangiocarcinoma.
Mertens JC; Ilyas SI; Gores GJ
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1454-1460. PubMed ID: 28844952
[TBL] [Abstract][Full Text] [Related]
3. Epigenome Remodeling in Cholangiocarcinoma.
O'Rourke CJ; Lafuente-Barquero J; Andersen JB
Trends Cancer; 2019 Jun; 5(6):335-350. PubMed ID: 31208696
[TBL] [Abstract][Full Text] [Related]
4. Molecular classification of cholangiocarcinoma.
Louis C; Papoutsoglou P; Coulouarn C
Curr Opin Gastroenterol; 2020 Mar; 36(2):57-62. PubMed ID: 31895230
[TBL] [Abstract][Full Text] [Related]
5. The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine.
Rimassa L; Personeni N; Aghemo A; Lleo A
J Autoimmun; 2019 Jun; 100():17-26. PubMed ID: 30862450
[TBL] [Abstract][Full Text] [Related]
6. The ATO/miRNA-885-5p/MTPN axis induces reversal of drug-resistance in cholangiocarcinoma.
Wang Y; Zhang W; Chen L; Chen W; Xu S; Tang L; Yang Y; Li Q; Jiang Q; Miao L
Cell Oncol (Dordr); 2021 Aug; 44(4):907-916. PubMed ID: 34170484
[TBL] [Abstract][Full Text] [Related]
7. The Co-mutational Spectrum Determines the Therapeutic Response in Murine FGFR2 Fusion-Driven Cholangiocarcinoma.
Kendre G; Marhenke S; Lorz G; Becker D; Reineke-Plaaß T; Poth T; Murugesan K; Kühnel F; Woller N; Wirtz RM; Pich A; Marquardt JU; Saborowski M; Vogel A; Saborowski A
Hepatology; 2021 Sep; 74(3):1357-1370. PubMed ID: 33709535
[TBL] [Abstract][Full Text] [Related]
8. Current challenges to underpinning the genetic basis for cholangiocarcinoma.
Cigliano A; Chen X; Calvisi DF
Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):511-526. PubMed ID: 33888034
[TBL] [Abstract][Full Text] [Related]
9. Cholangiocarcinoma: novel therapeutic targets.
Sato K; Glaser S; Alvaro D; Meng F; Francis H; Alpini G
Expert Opin Ther Targets; 2020 Apr; 24(4):345-357. PubMed ID: 32077341
[No Abstract] [Full Text] [Related]
10. Chemoresistance and chemosensitization in cholangiocarcinoma.
Marin JJG; Lozano E; Herraez E; Asensio M; Di Giacomo S; Romero MR; Briz O; Serrano MA; Efferth T; Macias RIR
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1444-1453. PubMed ID: 28600147
[TBL] [Abstract][Full Text] [Related]
11. Future directions in the treatment of cholangiocarcinoma.
Zhu AX
Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):355-61. PubMed ID: 25966434
[TBL] [Abstract][Full Text] [Related]
12. Cholangiocarcinoma 2020: the next horizon in mechanisms and management.
Banales JM; Marin JJG; Lamarca A; Rodrigues PM; Khan SA; Roberts LR; Cardinale V; Carpino G; Andersen JB; Braconi C; Calvisi DF; Perugorria MJ; Fabris L; Boulter L; Macias RIR; Gaudio E; Alvaro D; Gradilone SA; Strazzabosco M; Marzioni M; Coulouarn C; Fouassier L; Raggi C; Invernizzi P; Mertens JC; Moncsek A; Ilyas SI; Heimbach J; Koerkamp BG; Bruix J; Forner A; Bridgewater J; Valle JW; Gores GJ
Nat Rev Gastroenterol Hepatol; 2020 Sep; 17(9):557-588. PubMed ID: 32606456
[TBL] [Abstract][Full Text] [Related]
13. Cholangiocarcinoma: State of the Art.
Moazzami B; Majidzadeh-A K; Dooghaie-Moghadam A; Eslami P; Razavi-Khorasani N; Iravani S; Khoshdel A; Shahi F; Dashti H; Mehrvar A; Nassiri Toosi M
J Gastrointest Cancer; 2020 Sep; 51(3):774-781. PubMed ID: 32157571
[TBL] [Abstract][Full Text] [Related]
14. lnc-PKD2-2-3, identified by long non-coding RNA expression profiling, is associated with pejorative tumor features and poor prognosis, enhances cancer stemness and may serve as cancer stem-cell marker in cholangiocarcinoma.
Qiu G; Ma D; Li F; Sun D; Zeng Z
Int J Oncol; 2019 Jul; 55(1):45-58. PubMed ID: 31059014
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast-Derived Lysyl Oxidase Increases Oxidative Phosphorylation and Stemness in Cholangiocarcinoma.
Lewinska M; Zhuravleva E; Satriano L; Martinez MB; Bhatt DK; Oliveira DVNP; Antoku Y; Keggenhoff FL; Castven D; Marquardt JU; Matter MS; Erler JT; Oliveira RC; Aldana BI; Al-Abdulla R; Perugorria MJ; Calvisi DF; Perez LA; Rodrigues PM; Labiano I; Banales JM; Andersen JB
Gastroenterology; 2024 May; 166(5):886-901.e7. PubMed ID: 38096955
[TBL] [Abstract][Full Text] [Related]
16. Impact of microenvironment and stem-like plasticity in cholangiocarcinoma: molecular networks and biological concepts.
Raggi C; Invernizzi P; Andersen JB
J Hepatol; 2015 Jan; 62(1):198-207. PubMed ID: 25220250
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide screen identified let-7c/miR-99a/miR-125b regulating tumor progression and stem-like properties in cholangiocarcinoma.
Lin KY; Ye H; Han BW; Wang WT; Wei PP; He B; Li XJ; Chen YQ
Oncogene; 2016 Jun; 35(26):3376-86. PubMed ID: 26455324
[TBL] [Abstract][Full Text] [Related]
18. Cholangiocellular Carcinoma.
Vogel A; Saborowski A
Digestion; 2017; 95(3):181-185. PubMed ID: 28288474
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic Silencing of miRNA-34a in Human Cholangiocarcinoma via EZH2 and DNA Methylation: Impact on Regulation of Notch Pathway.
Kwon H; Song K; Han C; Zhang J; Lu L; Chen W; Wu T
Am J Pathol; 2017 Oct; 187(10):2288-2299. PubMed ID: 28923203
[TBL] [Abstract][Full Text] [Related]
20. Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma (Review).
Yang S; Zou R; Dai Y; Hu Y; Li F; Hu H
Int J Oncol; 2023 Dec; 63(6):. PubMed ID: 37888583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
